Romosozumab (Evenity) for Postmenopausal Osteoporosis
Date: June 3, 2019
Issue #:
1573Summary:
The FDA has approved romosozumab-aqqg (Evenity–
Amgen), a sclerostin inhibitor, for once-monthly
subcutaneous (SC) treatment of osteoporosis in
postmenopausal women who are at high risk
for fracture (history of osteoporotic fracture or
multiple risk factors for fracture) or who have failed
or cannot tolerate other drugs for this indication.
R omosozumab is the first sclerostin inhibitor to be
approved in the US and the third drug for treatment of
postmenopausal osteoporosis that stimulates bone
formation; the parathyroid hormone (PTH) receptor
agonists abaloparatide(Tymlos) and teriparatide(Forteo) were approved earlier. Other drugs used for
treatment of postmenopausal osteoporosis, such
as bisphosphonates, inhibit bone resorption and
decrease bone turnover.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: abaloparatide Aclasta Actonel Alendronate Atelvia Binosto Bisphosphonates Boniva Denosumab Evenity Evista Forteo Fosamax Fosavance Ibandronate Osteoporosis Postmenopausal osteoporosis Prolia Raloxifene Reclast rised Source Type: research
More News: Actonel | Boniva | Drugs & Pharmacology | Evista | Forteo | Hormones | Orthopaedics | Osteoporosis | Reclast | Risedronate | Women | Xgeva | Zometa